The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.
Article obtained from Photonics RSS Feed.
An agreement signed this month is poised to broaden the scope and application of fluorescence-labeled poly ADP-ribose polymerase (PARP) inhibitors in cancer detection and diagnostics. Summit Biomedical Imaging (SBI), a clinical stage developer of diagnostic medical imaging products, reached a global license agreement for intellectual property with medical imaging and biotechnology company Theragnostics. The agreement contributes to SBI’s global freedom to operate in the diagnostic field of certain fluorescence-labeled PARP inhibitors, as the company focuses on developing oral cancer detection applications bringing new diagnostic solutions to market.
PARP is a class of enzyme involved in the normal cellular processes. Cancerous…READ MORE